Actavis Raises Bid For Pliva; Will Barr Follow?
Actavis has increased its bid for the Croatian generic drug maker to roughly $2.5 bil., trumping Barr's $2.3 bil. offer.
Actavis has increased its bid for the Croatian generic drug maker to roughly $2.5 bil., trumping Barr's $2.3 bil. offer.